PD-1

39 programs · 39 companies

Programs
39
Companies
39
Active Trials
32
Targeting PD-1
DrugCompanyPhaseMOAIndications
JNJ-7458Johnson & JohnsonPhase 1/2JAK1iRCC
PexaosocimabDaiichi SankyoPhase 2JAK1iCervical CaOvarian Ca
MRN-8133ModernaPhase 2BTKiFabryUrothelial Ca
SemazasiranBeiGenePhase 1FXIaiNMOSD
RimainavolisibIlluminaPhase 2FGFRiPNH
MotanaritideIntelliaApprovedWEE1iThymomaPompe
452-5607EisaiPreclinicalHPK1iDMDUrothelial Ca
450-6746ShionogiApprovedHER2FSGS
ARX-3681Aroa BiosurgeryPhase 2Anti-AβRA
GUS-IIT-564Gustave RoussyPhase 3FcRniPSP
CAM-IIT-125CAMSPhase 1Cl18.2Obesity
DUK-IIT-810Duke Cancer InstitutePhase 1/2MALT1iPsoriasis
HOV-IIT-903HOVONPhase 1/2JAK1iParkinson's
ADI-2736Adicet (Regeneron)PreclinicalMeniniEwing Sarcoma
APT-892AptinyxApprovedBiTECholangiocarcinomaPNH
SPI-1775Spire BiotechPreclinicalKRASG12DiRBMeso
IMM-5415Immunomedics (Gilead)PreclinicalBCMA ADCParkinson'sWet AMD
MRN-6769Marinus PharmaPhase 2/3GLP-1/GIPUrothelial CaCLL
VRN-4215Verona PharmaPreclinicalAnti-TauCervical CaPNH
RLY-4615RallybioPhase 3WEE1iProstate Ca
CapisertibChina BiologicNDA/BLAJAK1/2iObesityUC
SotolemzoparlimabSierra Oncology (GSK)Phase 1BCL-2iHS
DatonesiranCelgene (BMS)NDA/BLAIL-17iProstate CaUC
DaraglumideKelun-BiotechPreclinicalPD-1iSchizophreniaCeliac
IvorasimodGC CellApprovedAnti-TauCKDPompe
DoxarelsinTreelinePhase 1/2HPK1iACCGBM
VAL-3792Valo HealthPhase 1/2Cl18.2Crohn'sCF
GelicilimabAlkermesPhase 3PD-L1iUCHuntington's
DatocapivasertibAldel BioNDA/BLAPD-1iFabry
MiricilimabNateraPhase 2BCL-2iHCC
MAP-6526Maplewood BioApprovedMeniniACCNMOSD
MEN-8522MenariniPhase 1CGRPantMGMM
FRX-2080Fennec PharmaPhase 2/3DLL3 ADCAlzheimer's
MIR-1203MiRXESPhase 1KRASG12DiDravetObesity
TezetenlimabLiomontPhase 2BTKiMGPSP
SEV-IIT-977Severance HospitalPhase 3GLP-1agCervical Ca
WST-4138West PharmaPhase 1/2GLP-1/GIPPTSDPSP
LiramavacamtenAceragenPreclinicalKRASG12CiUrothelial Ca
ZTS-7367ZoetisPreclinicalBTKiNarcolepsy